Inventiva has received a speculative strong buy rating with a fair value estimate of about $15 per share, significantly higher than its current price of around $3.20. This optimism follows positive Phase 2b results for lanifibranor, a drug targeting MASH, a serious liver disease. The upcoming Phase 3 NATiV3 trial readout is a major catalyst that could validate the drug's clinical benefits and market potential. However, risks remain including safety concerns, regulatory challenges, potential dilution, and competition from other therapies like GLP-1s. The trial outcome will be crucial in assessing lanifibranor's differentiation and adoption in the untreated MASH patient population.
Inventiva stock shows significant upside potential ahead of a pivotal liver disease readout. For readers following the health sector, here is Pluang's market snapshot as of Oct 14, 2026 14:41 WIB: Among 150 priced Health-sector US stocks tradable on Pluang, 76 rose and 70 fell today. Notable movers include ABEO at USD 4.51 with a 1-day change of -7.96% and a typical hold time on Pluang of 26 days, SYRE at USD 79.88 down 7.01%, and ALMS at USD 6.58 down 6.80%.
Vattenfall has contracted Fluence Energy to deliver a 254 MW, 1 GWh battery storage system at the Brunsbüttel site in Germany, set to be operational by the end of 2028. This project, one of Germany's largest battery storage facilities, will enhance g...
Shield appointed Michelle Clark, former HSBC surveillance leader, as Global Communications Surveillance Expert to enhance its AI-driven product strategy. Clark's 20+ years in global banking and expertise in regulatory compliance and AI innovation wil...
Phonak has introduced Roger On Sphere™, the world's first remote microphone using AI to separate speech from background noise in real time. This device enhances communication for people with hearing loss in noisy environments like restaurants and mee...
Southern Company, operating through Georgia Power, Alabama Power, and Mississippi Power, reported a data breach compromising customer personal information including names, addresses, Social Security numbers, and financial details. This breach raises ...
Intel's stock price has almost tripled in 2026, showing strong recent performance. However, a $10,000 investment in Intel made in 2016 would still be worth less than if it had been invested in the S&P 500 index. This highlights that despite recent ga...
